CA3037469C - Treatment of dermal disorders comprising a mtorc1 inhibitor - Google Patents

Treatment of dermal disorders comprising a mtorc1 inhibitor Download PDF

Info

Publication number
CA3037469C
CA3037469C CA3037469A CA3037469A CA3037469C CA 3037469 C CA3037469 C CA 3037469C CA 3037469 A CA3037469 A CA 3037469A CA 3037469 A CA3037469 A CA 3037469A CA 3037469 C CA3037469 C CA 3037469C
Authority
CA
Canada
Prior art keywords
dermal
composition
rapamycin
salt
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3037469A
Other languages
English (en)
French (fr)
Other versions
CA3037469A1 (en
Inventor
Christian Sell
Timothy NACARELLI
Ashley AZAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drexel University
Original Assignee
Drexel University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drexel University filed Critical Drexel University
Publication of CA3037469A1 publication Critical patent/CA3037469A1/en
Application granted granted Critical
Publication of CA3037469C publication Critical patent/CA3037469C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3037469A 2015-09-24 2016-09-19 Treatment of dermal disorders comprising a mtorc1 inhibitor Active CA3037469C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232228P 2015-09-24 2015-09-24
US62/232,228 2015-09-24
PCT/US2016/052442 WO2017053222A1 (en) 2015-09-24 2016-09-19 Novel compositions and methods for treating or preventing dermal disorders

Publications (2)

Publication Number Publication Date
CA3037469A1 CA3037469A1 (en) 2017-03-30
CA3037469C true CA3037469C (en) 2024-04-16

Family

ID=58387119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3037469A Active CA3037469C (en) 2015-09-24 2016-09-19 Treatment of dermal disorders comprising a mtorc1 inhibitor

Country Status (9)

Country Link
US (3) US10695326B2 (https=)
EP (2) EP4729121A2 (https=)
JP (3) JP2018528236A (https=)
KR (1) KR20180081501A (https=)
CN (2) CN108348508A (https=)
AU (1) AU2016325446B2 (https=)
CA (1) CA3037469C (https=)
ES (1) ES3060762T3 (https=)
WO (1) WO2017053222A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
CA3037469C (en) * 2015-09-24 2024-04-16 Drexel University Treatment of dermal disorders comprising a mtorc1 inhibitor
EP3496712A1 (en) * 2016-08-10 2019-06-19 The Board of Regents of The University of Texas System Topical rapamycin therapy
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CN112955126A (zh) * 2018-10-11 2021-06-11 德雷克塞尔大学 治疗或预防皮肤状况的方法
JP7516252B2 (ja) * 2018-11-02 2024-07-16 株式会社 資生堂 オルタナティブオートファジー誘導剤を含む紫外線起因性炎症抑制剤
KR102132921B1 (ko) * 2018-12-13 2020-07-13 영남대학교 산학협력단 조타로리무스를 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20040180430A1 (en) 1999-09-07 2004-09-16 West Michael D. Methods of restoring telomere length and extending cell lifespan using nuclear transfer
US7026374B2 (en) 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
EP1646635A1 (en) 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c
US20050250805A1 (en) * 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical ointment formulations
KR20070121746A (ko) 2005-03-14 2007-12-27 매크로켐 코포레이션 사람 피부를 통한 마크롤라이드 침투의 개선
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
MXPA06008797A (es) * 2006-08-03 2008-02-04 Fernando Ahumada Ayala Preparacion topica para el tratamiento de enfermedades inflamatorias de la piel que contiene sirolimus.
WO2008022256A2 (en) 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US20100278784A1 (en) 2007-05-15 2010-11-04 Puretech Ventures Methods and compositions for treating skin conditions
WO2009046436A1 (en) 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells
PT2362866E (pt) 2008-11-11 2015-10-26 Signum Biosciences Inc Compostos de isoprenila e métodos dos mesmos
BRPI1010655A2 (pt) 2009-04-10 2019-09-03 Qi Haiyan novos agentes antienvelhecimento e métodos para identificá-los
AU2013204219B2 (en) * 2009-04-10 2015-05-07 Haiyan Qi Novel anti-aging agents and methods to identify them
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2011079154A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
CA2825786A1 (en) * 2011-01-31 2012-08-09 Osaka University Externally-used drug for treating skin disorder and method for producing same
WO2012142145A1 (en) 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
WO2013070976A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
US20150202187A1 (en) 2012-06-26 2015-07-23 Sarah Bacus Compositions and methods for treatment of vitiligo
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
AU2014348657A1 (en) * 2013-11-13 2016-05-19 Novartis Ag mTOR inhibitors for enhancing the immune response
US9980976B2 (en) * 2015-02-17 2018-05-29 Northwestern University Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists
CA3037469C (en) * 2015-09-24 2024-04-16 Drexel University Treatment of dermal disorders comprising a mtorc1 inhibitor

Also Published As

Publication number Publication date
US20180280362A1 (en) 2018-10-04
JP2022009168A (ja) 2022-01-14
JP7573078B2 (ja) 2024-10-24
US10695326B2 (en) 2020-06-30
AU2016325446A1 (en) 2018-04-19
HK1258696A1 (en) 2019-11-15
KR20180081501A (ko) 2018-07-16
US20220031673A1 (en) 2022-02-03
EP3352755A4 (en) 2019-04-03
CN115645534A (zh) 2023-01-31
CA3037469A1 (en) 2017-03-30
EP4729121A2 (en) 2026-04-22
WO2017053222A1 (en) 2017-03-30
JP2023154020A (ja) 2023-10-18
EP3352755B1 (en) 2025-12-24
CN108348508A (zh) 2018-07-31
US20200281903A1 (en) 2020-09-10
JP7332666B2 (ja) 2023-08-23
AU2016325446B2 (en) 2021-05-13
EP3352755A1 (en) 2018-08-01
JP2018528236A (ja) 2018-09-27
US11179374B2 (en) 2021-11-23
ES3060762T3 (en) 2026-03-30

Similar Documents

Publication Publication Date Title
US11179374B2 (en) Compositions and methods for treating or preventing dermal disorders
US20240108645A1 (en) Senescence and senescence associated secretory phenotype
Lamming et al. Rapalogs and mTOR inhibitors as anti-aging therapeutics
Vin et al. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
US9555034B2 (en) Compositions and methods for treating skin cancer associated diseases
CN101155577B (zh) 神经纤维瘤的局部治疗
US20160000744A1 (en) Methods of Inhibiting IGF-1R Activation or Downtream Signalling Thereof to Reduce Radiation-Induced Cellular Senescence
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
Maia et al. Mitotherapy prevents peripheral neuropathy induced by oxaliplatin in mice
US9629851B2 (en) ROCK in combination with MAPK pathway
KR20120133389A (ko) 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
HK1258696B (en) Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis
SG11202110533RA (en) Methods and materials for gender-dependent treatment of cardiovascular dysfunction
WO2013059548A9 (en) Compositions and methods for treating cancer using jak2 inhibitor
US11759434B2 (en) Methods and compositions for treating melanoma and non-melanoma skin cancers
Keser et al. Comparative Analysis of CDK4/6 Inhibitors (Ribociclib and Palbociclib) combined with Enzalutamide in Triple-negative breast cancer cells
Sweeney Pre-clinical investigation of the effect of combining the cytotoxic agent Temozolomide with a dual mTORC2 inhibitor for the treatment of glioblastoma and establishment of an imageable surgical resection model of glioblastoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210913

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240911

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240911

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240911

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250909

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909